Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 25;61(20):9335-9346.
doi: 10.1021/acs.jmedchem.8b01249. Epub 2018 Oct 11.

Design of a True Bivalent Ligand with Picomolar Binding Affinity for a G Protein-Coupled Receptor Homodimer

Affiliations

Design of a True Bivalent Ligand with Picomolar Binding Affinity for a G Protein-Coupled Receptor Homodimer

Daniel Pulido et al. J Med Chem. .

Abstract

Bivalent ligands have emerged as chemical tools to study G protein-coupled receptor dimers. Using a combination of computational, chemical, and biochemical tools, here we describe the design of bivalent ligand 13 with high affinity ( KDB1 = 21 pM) for the dopamine D2 receptor (D2R) homodimer. Bivalent ligand 13 enhances the binding affinity relative to monovalent compound 15 by 37-fold, indicating simultaneous binding at both protomers. Using synthetic peptides with amino acid sequences of transmembrane (TM) domains of D2R, we provide evidence that TM6 forms the interface of the homodimer. Notably, the disturber peptide TAT-TM6 decreased the binding of bivalent ligand 13 by 52-fold and had no effect on monovalent compound 15, confirming the D2R homodimer through TM6 ex vivo. In conclusion, by using a versatile multivalent chemical platform, we have developed a precise strategy to generate a true bivalent ligand that simultaneously targets both orthosteric sites of the D2R homodimer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1.
Figure 1.
A) Components for the design of bivalent ligands. B) Bivalent ligands (1213) and their corresponding monovalent counterparts (1415).
Scheme 1.
Scheme 1.
a Synthesis of the bivalent ligands 12 and 13 and the monovalent ligands 14 and 15. a Reagents and conditions: (a) 10, EDC·HCl, HOBt·H2O, DIEA, DMF, rt, 16 h (49%); (b) 11, EDC·HCl, HOBt·H2O, DIEA, DMF, rt, 16 h (64%); (c) EDC·HCl, dry DMF, rt, 2 h, then 8, DIEA, dry DMF, rt, 90 min (79%); (d) 10, EDC·HCl, HOBt·H2O, DIEA, DMF, rt, 16 h (25%); (e) EDC·HCl, dry DMF, rt, 2 h, then 9, DIEA, dry DMF, rt, 90 min (80%); (f) 11, EDC·HCl, HOBt·H2O, DIEA, DMF, rt, 16 h (24%).
Figure 2.
Figure 2.
Antagonistic effect of the studied compounds on global cellular response induced by sumanirole. Dynamic mass redistribution (DMR) assays were performed in CHO cells stably expressing D2R and A2AR. A) Quantification of the antagonist effect of all D2R ligands on DMR. Values are mean±SEM from 3 determinations carried out in triplicates. Statistical significance was calculated by one-way ANOVA followed by Dunnett’s post hoc test. **p<0.01 compared to sumanirole alone. B) Representative DMR curves from one of these experiments in which cells were treated with medium (control) (black), with 1μM of spiperone (grey), with 1μM of monovalent compounds 14 (light blue) or 15 (dark blue) or with 500 nM of bivalent compounds 12 (orange) or 13 (red) for 30 minutes. After that, cells were treated with 100 nM of sumanirole. Each curve is the mean of a representative optical trace experiment carried out in triplicates. The resulting shifts of reflected light wavelength (pm) were monitored over time. C) Dose-response of the antagonistic effect of bivalent compound 13 (black) (IC50=15±3 nM) and monovalent 15 (red) (IC50=280±70 nM) on the DMR induced by 100 nM sumanirole. Data are mean±SEM from 3–8 experiments and are presented as percentage of the maximal effect of sumanirole.
Figure 3.
Figure 3.
Effect of TAT-TM peptides on disturbance of the D2R homodimer, determined by BiFC experiments in HEK-293T cells transfected with D2R-nYFP and D2R-cYFP cDNA. Values are mean±SEM from 6–9 determinations. Statistical significance was calculated by one-way ANOVA followed by Bonferroni’s post hoc test. ***p<0.001 compared to non TAT-TM treated complementation.
Figure 4.
Figure 4.
Effect of TAT-TM6 peptides of D2R and A2AR on competition experiments of [3H]YM-09151–2 vs. D2R ligands. Competition curves with increasing concentrations of monovalent 15 (in A) or bivalent 13 (in B) D2R ligands in the absence (black) or in the presence of TAT-TM6 of A2AR (red) or TAT-TM6 of D2R (blue), using membranes from sheep brain striatum. Data are mean±SEM from 3 experiments performed in triplicate.
Figure 5.
Figure 5.
Evolution of bivalent ligand 13 in the D2R homodimer (TM1 and TM4, ECL1 and part of ECL2 are omitted for clarity), constructed via the TM6 interface, as devised from MD simulations. The structures of 13 (the color code of the atoms is as in Figure 1) are extracted from the simulations (20 structures collected every 50 ns), whereas the structure of the D2R homodimer corresponds to the initial model. A detailed analysis of the simulation (Figure S3) confirms that the designed bivalent ligand 13 remains stable at the orthosteric binding cavities through the unbiased 1 μs MD simulation.

Similar articles

Cited by

References

    1. Whorton MR; Bokoch MP; Rasmussen SGF; Huang B; Zare RN; Kobilka B; Sunahara RK A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. Proc. Natl. Acad. Sci. USA 2007, 104, 7682–7687. - PMC - PubMed
    1. Ferré S; Casadó V; Devi LA; Filizola M; Jockers R; Lohse MJ; Milligan G; Pin JP; Guitart X. G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol. Rev 2014, 66, 413–434. - PMC - PubMed
    1. Farran B. An update on the physiological and therapeutic relevance of GPCR oligomers. Pharmacol. Res 2017, 117, 303–327. - PubMed
    1. Santos R; Ursu O; Gaulton A; Bento AP; Donadi RS; Bologa CG; Karlsson A; Al-Lazikani B; Hersey A; Oprea TI; Overington JP A comprehensive map of molecular drug targets. Nat. Rev. Drug Discovery 2017, 16, 19–34. - PMC - PubMed
    2. Gaitonde SA; González-Maeso J. Contribution of heteromerization to G protein-coupled receptor function. Curr. Opin. Pharmacol 2017, 32, 23–31. - PMC - PubMed
    1. Guo H; An S; Ward R; Yang Y; Liu Y; Guo XX; Hao Q; Xu TR Methods used to study the oligomeric structure of G-protein-coupled receptors. Biosci. Rep 2017, 37, BSR20160547. - PMC - PubMed

Publication types

LinkOut - more resources